Table 1.

Higher dexamethasone clearance was associated with cumulative incidence of any (hematologic, CNS, and other) relapse

Factors*	Hazard ratio	95% CI	P†
Dexamethasone CL/F (L/h per m2) per 50-unit change‡	1.56	1.1-2.19	.0104
Anti–ASP antibody positive vs negative	0.57	0.09-3.76	.56
ASP antibody timing§	0.74	0.23-2.36	.61
Older than 10 years vs 1-10 years	0.61	0.23-1.59	.31
Initial leukocyte count ≥ 100 cells/mm3 vs < 100 cells/mm3	1.87	0.57-6.16	.30
Black vs white‖	2.84	1.13-7.1	.0261
Other vs white‖	1.22	0.33-4.42	.76
T-lineage vs B-lineage¶	1.63	0.67-4.0	.28
MRD 46 positive vs negative#	1.31	0.48-3.62	.60
SR/HR vs LR	5.99	1.80-19.97	.0035

ASP indicates asparaginase; and MRD 46, minimal residual disease at the end of remission induction.

^*Prognostic features included in this model are known to be associated with treatment outcome in St Jude Total XV cohort by univariate analysis.⁹

^†P value from multivariate analysis using Fine and Gray regression model.¹⁸

^‡Dexamethasone clearance is continuous variable, and the hazard ratio is calculated for every 50-unit change in clearance.

^§Timing when the patients first tested positive for anti–asparaginase antibody.

^‖Genetically determined race as described.¹⁰

^¶Acute lymphoblastic leukemia immunophenotype.

^#MRD positive is ≥ 0.01% (1 or more lymphoblasts among 10⁴ mononuclear cells in the bone marrow) and MRD negative is < 0.01% lymphoblasts in the bone marrow sample.